|
US20030044384A1
(en)
*
|
1997-10-09 |
2003-03-06 |
Pro-Virus, Inc. |
Treatment of neoplasms with viruses
|
|
EP1955703A1
(en)
|
1999-11-12 |
2008-08-13 |
Oncolytics Biotech Inc. |
Viruses for the treatment of cellular proliferative disorders
|
|
AUPQ425699A0
(en)
|
1999-11-25 |
1999-12-23 |
University Of Newcastle Research Associates Limited, The |
A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
|
|
JP2004508277A
(ja)
*
|
1999-12-08 |
2004-03-18 |
オニックス ファーマシューティカルズ，インコーポレイティド |
不所望の過剰増殖性細胞増殖を治療するための単純ヘルペスウイルス
|
|
AR028040A1
(es)
*
|
2000-05-03 |
2003-04-23 |
Oncolytics Biotech Inc |
Remocion de virus de celulas neoplasticas a partir de composiciones celulares mixtas
|
|
US7306902B2
(en)
|
2002-06-28 |
2007-12-11 |
Oncolyties Biotech Inc. |
Oncolytic viruses as phenotyping agents for neoplasms
|
|
US8491884B2
(en)
|
2000-05-03 |
2013-07-23 |
Oncolytics Biotech Inc. |
Virus clearance of neoplastic cells from mixed cellular compositions
|
|
AR028039A1
(es)
|
2000-05-03 |
2003-04-23 |
Oncolytics Biotech Inc |
Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
|
|
US20020147996A1
(en)
*
|
2000-07-07 |
2002-10-10 |
Benjamin Thomas L. |
Diagnosing and treating cancer cells using Sal2
|
|
US20030157481A1
(en)
*
|
2001-12-10 |
2003-08-21 |
Benjamin Thomas L. |
Diagnosing and treating cancer cells using T-HR mutants and their targets
|
|
US20020156039A1
(en)
*
|
2000-07-07 |
2002-10-24 |
Benjamin Thomas L. |
Diagnosing and treating cancer cells using Sal2
|
|
US20050013803A1
(en)
*
|
2000-07-07 |
2005-01-20 |
Benjamin Thomas L. |
Diagnosing and treating cancer cells using mutant viruses
|
|
US6982251B2
(en)
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
|
IL156445A0
(en)
|
2001-01-26 |
2004-01-04 |
Schering Corp |
Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
|
US7071181B2
(en)
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
|
AR035533A1
(es)
|
2001-01-26 |
2004-06-02 |
Schering Corp |
Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
|
|
AR035227A1
(es)
*
|
2001-02-20 |
2004-05-05 |
Oncolytics Biotech Inc |
Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
|
|
US7056906B2
(en)
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
|
MXPA04002573A
(es)
|
2001-09-21 |
2004-06-18 |
Schering Corp |
Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
|
|
US7053080B2
(en)
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
|
US6844000B2
(en)
*
|
2001-12-07 |
2005-01-18 |
Bayer Pharmaceuticals Corporation |
Use of Parapox B2L protein to treat cancer and modify immune responses
|
|
EP1605053A1
(en)
*
|
2002-03-26 |
2005-12-14 |
Oncolytics Biotech Inc. |
Use of adenoviruses mutated in the VA genes for cancer treatment
|
|
US20040180438A1
(en)
*
|
2002-04-26 |
2004-09-16 |
Pachuk Catherine J. |
Methods and compositions for silencing genes without inducing toxicity
|
|
WO2003090676A2
(en)
*
|
2002-04-26 |
2003-11-06 |
Wellstat Biologics Corporation |
Immunogenic agent therapy using plasmapheresis or exchange transfusion
|
|
WO2004009763A2
(en)
|
2002-07-24 |
2004-01-29 |
Arizona Board Of Regents |
Use of vaccinia virus deleted for the e3l gene as a vaccine vector
|
|
EP2269619A1
(en)
|
2002-08-12 |
2011-01-05 |
Jennerex Biotherapeutics ULC |
Methods and compositions concerning poxviruses and cancer
|
|
WO2004043457A1
(en)
|
2002-11-06 |
2004-05-27 |
Schering Corporation |
Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
|
|
AU2002953436A0
(en)
|
2002-12-18 |
2003-01-09 |
The University Of Newcastle Research Associates Limited |
A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
|
|
CA2517572C
(en)
|
2003-03-07 |
2011-12-13 |
Schering Corporation |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
|
|
US7459442B2
(en)
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
|
JP2006519869A
(ja)
|
2003-03-07 |
2006-08-31 |
シェーリング コーポレイション |
置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
|
|
EP1601668B1
(en)
|
2003-03-07 |
2008-08-27 |
Schering Corporation |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
|
|
EP1644492B1
(en)
|
2003-06-18 |
2009-01-07 |
Genelux Corporation |
Modified recombinant vaccinia viruses, uses thereof
|
|
US20070036758A1
(en)
*
|
2003-07-08 |
2007-02-15 |
Bertram Jacobs |
Mutants of vaccinia virus as oncolytic agents
|
|
US7442372B2
(en)
|
2003-08-29 |
2008-10-28 |
Biomarin Pharmaceutical Inc. |
Delivery of therapeutic compounds to the brain and other tissues
|
|
US7429481B2
(en)
*
|
2004-09-14 |
2008-09-30 |
University Of Pittsburgh |
Targeting viruses using a modified sindbis glycoprotein
|
|
WO2006071966A2
(en)
*
|
2004-12-29 |
2006-07-06 |
The Brigham And Women's Hospital, Inc. |
Rapamycin compounds in the treatment of neurofibromatosis type 1
|
|
AU2006218115B2
(en)
|
2005-02-23 |
2012-08-02 |
Bavarian Nordic A/S |
Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents
|
|
AU2006222500B2
(en)
*
|
2005-03-07 |
2011-09-01 |
Robarts Research Institute |
Use of a combination of Myxoma virus and rapamycin for therapeutic treatment
|
|
US20070004767A1
(en)
*
|
2005-06-30 |
2007-01-04 |
Gutmann David H |
Methods for treating neurofibromatosis 1
|
|
WO2007099401A2
(en)
|
2005-08-01 |
2007-09-07 |
University Technologies International, Inc. |
Oncolytic attenuated reoviruses for treatment of proliferative disorders
|
|
US10668119B2
(en)
|
2005-08-01 |
2020-06-02 |
Virocure, Inc. |
Attenuated reovirus
|
|
KR101772375B1
(ko)
|
2005-09-07 |
2017-08-29 |
신라젠(주) |
Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법
|
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
|
US20070190032A1
(en)
*
|
2006-02-13 |
2007-08-16 |
Oncolytics Biotech Inc. |
Use of Local Immune Suppression to Enhance Oncolytic Viral Therapy
|
|
EP2426142A3
(en)
*
|
2006-10-16 |
2012-06-13 |
Genelux Corporation |
Modified vaccinia virus strains for use in a diagnostic and therapeutic method
|
|
US10369171B2
(en)
|
2007-03-13 |
2019-08-06 |
Virocure, Inc. |
Attenuated reoviruses for selection of cell populations
|
|
JP5213075B2
(ja)
|
2007-06-15 |
2013-06-19 |
ジェネラックス・コーポレイション |
腫瘍の画像化および／または処置のための微生物
|
|
WO2009011924A1
(en)
*
|
2007-07-18 |
2009-01-22 |
Genelux Corporation |
Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
|
|
WO2009135614A2
(en)
*
|
2008-05-09 |
2009-11-12 |
Bayer Schering Pharma Aktiengesellschaft |
Use of a virus regimen for the treatment of diseases
|
|
WO2009139921A2
(en)
*
|
2008-05-16 |
2009-11-19 |
Genelux Corporation |
Microorganisms for preventing and treating neoplasms accompanying cellular therapy
|
|
MX339014B
(es)
*
|
2008-05-27 |
2016-05-09 |
Oncolytics Biotech Inc |
Modulacion de presion intersticial y suministro y distribucion viral oncolitica.
|
|
EP2365802B1
(en)
|
2008-11-11 |
2017-08-02 |
The Board of Regents,The University of Texas System |
Microcapsules of rapamycin and use for treating cancer
|
|
BR112012005774B8
(pt)
|
2009-09-14 |
2023-02-14 |
Jennerex Inc |
uso de um inibidor de quinase antiangiogênico no tratamento de câncer
|
|
US9283211B1
(en)
|
2009-11-11 |
2016-03-15 |
Rapamycin Holdings, Llc |
Oral rapamycin preparation and use for stomatitis
|
|
KR101942237B1
(ko)
|
2011-01-04 |
2019-01-25 |
신라젠(주) |
종양 항원에 대한 항체의 생산 및 종양용해 우두 바이러스의 투여에 의한 종양 특이적 보체 의존적 세포독성의 생산
|
|
WO2012122649A1
(en)
*
|
2011-03-15 |
2012-09-20 |
Ottawa Hospital Research Institute |
Recombinant orf virus
|
|
CN114262690A
(zh)
|
2011-04-15 |
2022-04-01 |
吉恩勒克斯公司 |
减毒的痘苗病毒的克隆毒株及其使用方法
|
|
US8859256B2
(en)
|
2011-10-05 |
2014-10-14 |
Genelux Corporation |
Method for detecting replication or colonization of a biological therapeutic
|
|
EP2968281B1
(en)
|
2013-03-13 |
2020-08-05 |
The Board of Regents of The University of Texas System |
Mtor inhibitors for prevention of intestinal polyp growth
|
|
AU2014236207B2
(en)
|
2013-03-14 |
2019-05-23 |
Salk Institute For Biological Studies |
Oncolytic adenovirus compositions
|
|
DE102013105144A1
(de)
*
|
2013-05-17 |
2014-11-20 |
Arno Thaller |
Pharmazeutisches Kombinationspräparat mit einem anti-idiotypischen Antikörperfragment
|
|
US9700544B2
(en)
|
2013-12-31 |
2017-07-11 |
Neal K Vail |
Oral rapamycin nanoparticle preparations
|
|
AU2014373683B2
(en)
|
2013-12-31 |
2020-05-07 |
Rapamycin Holdings, Llc |
Oral rapamycin nanoparticle preparations and use
|
|
KR20250081944A
(ko)
|
2014-09-24 |
2025-06-05 |
솔크 인스티튜트 포 바이올로지칼 스터디즈 |
종양 살상 바이러스 및 이의 사용방법
|
|
BR112017008399A2
(pt)
|
2014-10-24 |
2018-06-19 |
StemImmune, Incorporated |
abordagem de imunoterapia de combinação para tratamento de câncer
|
|
EP4122492A1
(en)
|
2015-02-25 |
2023-01-25 |
Memorial Sloan Kettering Cancer Center |
Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
|
|
KR20180006916A
(ko)
|
2015-04-17 |
2018-01-19 |
메모리얼 슬로안-케터링 캔서 센터 |
고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도
|
|
HK1248588A1
(zh)
|
2015-08-11 |
2018-10-19 |
Calidi Biotherapeutics, Inc. |
用於癌症治疗中的天花疫苗
|
|
EP3778881A1
(en)
|
2016-01-08 |
2021-02-17 |
Replimune Limited |
Modified oncolytic virus
|
|
CN105754952B
(zh)
*
|
2016-02-16 |
2020-07-10 |
中国农业科学院兰州兽医研究所 |
抗羊痘病毒k3l蛋白c末端的单克隆抗体及其应用
|
|
EP4155411A1
(en)
|
2016-02-23 |
2023-03-29 |
Salk Institute for Biological Studies |
Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
|
|
WO2017147265A1
(en)
|
2016-02-23 |
2017-08-31 |
Salk Institute For Biological Studies |
High throughput assay for measuring adenovirus replication kinetics
|
|
JP7025339B2
(ja)
|
2016-02-25 |
2022-02-24 |
メモリアル スローン ケタリング キャンサー センター |
癌免疫療法のための、チミジンキナーゼの欠失を伴い、ヒトｆｌｔ３ｌまたはｇｍ－ｃｓｆの発現を伴うかまたは伴わない、複製可能な弱毒化ワクシニアウイルス
|
|
CN109152827B
(zh)
|
2016-02-25 |
2023-07-21 |
纪念斯隆凯特琳癌症中心 |
重组mva或表达人flt3l的mvaδe3l及其作为抗固体肿瘤的免疫治疗剂的用途
|
|
JP2019509326A
(ja)
*
|
2016-03-25 |
2019-04-04 |
ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション |
合成エンベロープ化ウイルス
|
|
US10842835B2
(en)
|
2016-05-25 |
2020-11-24 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Oncolytic vaccinia virus mutants and using same for cancer treatment
|
|
KR102190326B1
(ko)
*
|
2016-07-21 |
2020-12-11 |
코오롱생명과학 주식회사 |
재조합 백시니아 바이러스 및 이의 용도
|
|
EP3532082A4
(en)
|
2016-12-12 |
2020-08-26 |
Salk Institute for Biological Studies |
SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
|
|
GB201700350D0
(en)
|
2017-01-09 |
2017-02-22 |
Replimune Ltd |
Altered virus
|
|
EP3621646A4
(en)
|
2017-05-12 |
2021-06-02 |
Memorial Sloan Kettering Cancer Center |
VACCINIA VIRUS MUTANTS FOR CANCER IMMUNOTHERAPY
|
|
US10610583B2
(en)
|
2017-08-31 |
2020-04-07 |
Regents Of The University Of Minnesota |
Methods and compositions for treating glioma and medulloblastoma brain tumors using the zika virus
|
|
WO2019143201A1
(ko)
*
|
2018-01-19 |
2019-07-25 |
코오롱생명과학 주식회사 |
재조합 백시니아 바이러스 및 이를 포함하는 약학 조성물
|
|
MX2020010499A
(es)
|
2018-04-09 |
2020-10-28 |
Salk Inst For Biological Studi |
Composiciones de adenovirus oncoliticas con propiedades aumentadas de replicacion.
|
|
US11505782B2
(en)
|
2018-06-04 |
2022-11-22 |
Calidi Biotherapeutics, Inc. |
Cell-based vehicles for potentiation of viral therapy
|
|
BR112021004692A2
(pt)
|
2018-09-15 |
2021-06-08 |
Memorial Sloan Kettering Cancer Center |
poxvírus recombinantes para imunoterapia de câncer
|
|
CN114364390A
(zh)
*
|
2019-08-26 |
2022-04-15 |
拜耳诺克斯有限公司 |
用于治疗癌症的包含抗癌病毒、免疫检查点抑制剂和羟基脲作为活性成分的药物组合物
|